Management of Papillary Thyroid Microcarcinoma

Juan P Brito; Ian D Hay

doi:10.1016/j.ecl.2018.10.006

Management of Papillary Thyroid Microcarcinoma

Endocrinol Metab Clin North Am. 2019 Mar;48(1):199-213. doi: 10.1016/j.ecl.2018.10.006. Epub 2018 Dec 23.

Authors

Juan P Brito¹, Ian D Hay²

Affiliations

¹ Division of Diabetes, Endocrinology, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA; Knowledge and Evaluation Research Unit, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA. Electronic address: brito.juan@mayo.edu.
² Division of Diabetes, Endocrinology, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.

PMID: 30717902
DOI: 10.1016/j.ecl.2018.10.006

Abstract

The worldwide incidence of thyroid cancer is increasing. A third of new thyroid cancer cases are papillary thyroid microcarcinoma (PTM), which are 1 cm or less. These tumors are mostly indolent with excellent prognosis. Although thyroid surgery is the most common management option for patients with PTM, new management options demand that treatment decisions must be individualized and based on patient's preference, context, and biology. This article describes management options for PTM patients and shared decision-making as a novel method for individualizing care.

Keywords: Management; Microcarcinoma; Papillary thyroid cancer; Shared decision-making.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Carcinoma, Papillary / drug therapy
Carcinoma, Papillary / radiotherapy
Carcinoma, Papillary / surgery
Carcinoma, Papillary / therapy*
Humans
Thyroid Neoplasms / drug therapy
Thyroid Neoplasms / radiotherapy
Thyroid Neoplasms / surgery
Thyroid Neoplasms / therapy*

Supplementary concepts

Papillary Thyroid Microcarcinoma